Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Matthieu Sarabi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4588-0585; OpenAlex author ID A5022977681. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 10

  1. Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study. Co-author DOI 10.1016/j.esmogo.2025.100144↗
  2. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  3. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Co-author DOI 10.1038/s41416-022-01713-w↗
  4. Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world A… Co-author DOI 10.1038/s41416-022-01734-5↗
  5. A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3. Co-author DOI 10.3390/jpm12040623↗
  6. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Co-author DOI 10.1038/s41416-021-01341-w↗
  7. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Co-author DOI 10.1053/j.gastro.2019.12.009↗
  8. Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis. Co-author DOI 10.1634/theoncologist.2018-0786↗
  9. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study. Co-author DOI 10.3747/co.26.4903↗
  10. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Co-author DOI 10.3892/ol.2017.6061↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christelle de la Fouchardière · 5 shared papers, 2017–2022 · strength 0.51
  2. Édouard Auclin · 3 shared papers, 2021–2022 · strength 0.36
  3. Julien Taı̈eb · 3 shared papers, 2021–2022 · strength 0.36
  4. David Tougeron · 3 shared papers, 2021–2022 · strength 0.36
  5. Pauline Rochefort · 3 shared papers, 2019–2022 · strength 0.33
  6. Sonia Zaibet · 2 shared papers, 2022 · strength 0.26
  7. Astrid Lièvre · 2 shared papers, 2022 · strength 0.26
  8. Dominique Béchade · 2 shared papers, 2022 · strength 0.26
  9. Julien Edeline · 2 shared papers, 2022 · strength 0.26
  10. Simon Pernot · 2 shared papers, 2022 · strength 0.26
  11. Marine Gilabert · 2 shared papers, 2022 · strength 0.26
  12. Sophie Bachy · 1 shared paper, 2022 · strength 0.12
  13. Anà Hennino · 1 shared paper, 2022 · strength 0.12
  14. Raëf Abdallah · 1 shared paper, 2021 · strength 0.10
  15. Léo Mas · 1 shared paper, 2021 · strength 0.10
  16. Angélique Vienot · 1 shared paper, 2021 · strength 0.10
  17. António Sá Cunha · 1 shared paper, 2021 · strength 0.10
  18. Lysiane Marthey · 1 shared paper, 2021 · strength 0.10
  19. Jean‐Baptiste Bachet · 1 shared paper, 2021 · strength 0.10
  20. Nicolas Williet · 1 shared paper, 2021 · strength 0.10
  21. Romain Coriat · 1 shared paper, 2021 · strength 0.10
  22. Éric François · 1 shared paper, 2021 · strength 0.10
  23. Elise Bonnet · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.